Novartis Ag (NVS) Change in Inventory (2010 - 2025)
Novartis Ag (NVS) posted Change in Inventory of $55.0 million for Q1 2025, up 142.97% sequentially from -$128.0 million in Q1 2024, and up 142.97% YoY from $22.6 million in Q1 2024.
Novartis Ag (NVS) Change in Inventory (2010 - 2025) Analysis & Trends
Novartis Ag has reported Change in Inventory for 7 years, with the latest figure at $55.0 million in Q1 2025.
- Quarterly Change in Inventory rose 142.97% year-over-year to $55.0 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was -$1.1 billion (down 4092.86% YoY) and the FY2017 annual result came in at $893.0 million, changed N/A from the prior year.
- Change in Inventory rose to $55.0 million in Q1 2025 per NVS's latest filing, from -$128.0 million in the prior quarter.
- Over five years, Change in Inventory peaked at $55.0 million in Q1 2025 and troughed at -$620.0 million in Q1 2023.
- A 4-year average of -$279.5 million and a median of -$276.5 million in 2022 frame the typical range for Change in Inventory.
- The sharpest annual moves came in 2023 and 2025: Change in Inventory sank 45.88% in 2023, then surged 142.97% in 2025.
- Over 4 years, Change in Inventory stood at -$425.0 million in 2022, then slumped by 45.88% to -$620.0 million in 2023, then surged by 79.35% to -$128.0 million in 2024, then soared by 142.97% to $55.0 million in 2025.
- According to Business Quant data, Change in Inventory over the past three periods registered $55.0 million, -$128.0 million, and -$620.0 million for Q1 2025, Q1 2024, and Q1 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 571.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 143.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 31.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 145.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 55.00 Mn |
| Mar 31, 2025 | 55.00 Mn |
| Mar 31, 2024 | -128.00 Mn |
| Mar 31, 2024 | -128.00 Mn |
| Mar 31, 2023 | -620.00 Mn |
| Mar 31, 2023 | -620.00 Mn |
| Mar 31, 2022 | -425.00 Mn |
| Mar 31, 2022 | -425.00 Mn |
| Dec 31, 2012 | 1.20 Bn |
| Dec 31, 2012 | 1.20 Bn |
| Sep 30, 2012 | 107.00 |
| Sep 30, 2012 | 107.00 |
| Mar 31, 2012 | 15.00 |
| Mar 31, 2012 | 15.00 |
| Dec 31, 2011 | -1.45 Bn |
| Dec 31, 2011 | -1.45 Bn |
| Sep 30, 2011 | -10.00 |
| Sep 30, 2011 | -10.00 |
| Jun 30, 2011 | 239.00 |
| Jun 30, 2011 | 239.00 |